The FDA approved Gilead Sciences (NASDAQ: GILD) Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg, a once-daily single-tablet HIV regimen) on Thursday August 27, 2026 for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen for at least 6 months and have no history of treatment failure or known resistance to bictegravir or lenacapavir. Approval was based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials presented at CROI 2026, both of which met non-inferiority for virologic suppression at Week 48 with a tolerable safety profile. Lenacapavir is Gilead's first-in-class HIV-1 capsid inhibitor (already approved as long-acting subcutaneous Sunlenca), and Bixlenvo is the first oral single-tablet regimen anchored on capsid inhibition. Dosing requires a two-day initiation period with Sunlenca before switching to Bixlenvo alone. The approval extends the single-tablet regimen category to an estimated 5%+ of U.S. HIV-suppressed adults on complex multi-pill regimens who could not previously use one-tablet options.
Roivant Sciences (NASDAQ: ROIV) subsidiary Priovant Therapeutics announced FDA approval of Lisraya (brepocitinib 30 mg once daily, a first-in-class TYK2/JAK1 dual selective inhibitor) on Thursday August 27, 2026 for adults with dermatomyositis (DM), an autoimmune inflammatory myopathy with skin involvement and few effective targeted therapies. Approval was based on the 52-week Phase 3 VALOR trial (241 patients, the longest and largest interventional DM study), where 55% of Lisraya patients achieved moderate-or-better improvement on the Total Improvement Score with minimal-or-no steroid use versus 30% on placebo. VALOR results were published in NEJM in March 2026 with dermatology secondary endpoints in JAMA Dermatology in August 2026. List price is $35,000 for a 30-day supply, with a $0/month patient support program for eligible patients. Brepocitinib was originally discovered by Pfizer and licensed to Priovant. Not a peptide; the approval matters here because dermatomyositis is one of several autoimmune indications where peptide immunomodulators (thymalfasin, thymosin alpha-1 analogs) had been discussed in earlier decades before being displaced by targeted small-molecule and biologic approaches.
Alongside the FDA approval announcement Thursday August 27, 2026, Roivant Sciences (NASDAQ: ROIV) filed an 8-K disclosure and hosted a conference call Friday August 28, 2026 confirming that Priovant Therapeutics has fielded a dermatology-and-rheumatology-focused sales force, contracted with major specialty pharmacy distributors, and secured initial payer coverage sufficient to begin U.S. commercial launch on August 28. Priovant is a Pfizer-Roivant joint venture (Roivant 75%, Pfizer 25%) that was created in 2022 specifically to advance brepocitinib in dermatomyositis, cutaneous lupus, and non-infectious uveitis. Beyond Lisraya, Priovant's brepocitinib program continues in Phase 3 for cutaneous lupus (VALIANT) with topline data expected in H1 2027 and in Phase 2 for non-infectious uveitis. The launch is a signal event for the Roivant 'Vant' model, in which spin-out subsidiaries develop and commercialize discrete assets while remaining consolidated within the parent. Not a peptide; included because the JAK/TYK2 inhibitor category continues to displace older peptide-based immunomodulation approaches in autoimmune disease.
The FDA on Wednesday August 26, 2026 approved Rasonque (daraxonrasib, a once-daily oral pan-RAS inhibitor developed by Revolution Medicines) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi-agent chemotherapy. Approval was based on the Phase 3 RASolute 302 trial across 500 previously-treated patients showing median overall survival of 13.2 months on Rasonque versus 6.7 months on standard chemotherapy. The drug does not require a companion diagnostic and is approved for patients with or without an identifiable RAS tumor mutation. FDA granted Breakthrough Therapy and Orphan Drug designations plus Priority Review. Daraxonrasib is a small molecule and not a peptide; the approval matters to peptide-relevant readers because it hardens the oncology backdrop the neoantigen peptide vaccine class (Merck-Moderna intismeran, individualized long-peptide programs) is entering, and because it validates a new mechanism class in a tumor where five-year survival has stalled near 13% for two decades.
Biohaven Ltd. (NYSE: BHVN) on Wednesday August 26, 2026 signed an exclusive, royalty-bearing worldwide license with SK Biopharmaceuticals for its Kv7 ion channel platform led by opakalim (BHV-7000, a selective Kv7.2/7.3 potassium channel activator in Phase 2/3 for focal epilepsy). Deal terms: upfront and milestone payments up to $795 million plus tiered royalties from the mid-teens to low twenties on U.S. net sales of opakalim, with SK Biopharmaceuticals responsible for development, regulatory filings, and commercialization in the United States, Europe, and Japan. The Phase 2/3 RISE3 trial for opakalim is ongoing with topline data expected in H2 2026. Biohaven shares jumped roughly 13% on the announcement. Opakalim is a small-molecule ion channel activator and not a peptide; the deal is included here because it is one of the largest neuroscience licensing transactions of the year and continues the pattern of Korean pharma partners (SK, Hanmi, Yuhan) becoming serious in-licensing counterparties for U.S. biotechs seeking non-dilutive capital.
Nicox SA (Euronext: COX) announced Wednesday August 26, 2026 that the FDA accepted the New Drug Application for NCX 470 (bimatoprost-nitric oxide donor, a once-daily topical eye drop for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension) with a PDUFA target action date of April 30, 2027. NCX 470 combines the FDA-approved prostaglandin analog bimatoprost with a nitric-oxide-releasing moiety intended to add trabecular meshwork outflow to the standard uveoscleral outflow mechanism, and completed two positive Phase 3 studies (Mont Blanc and Denali). Not a peptide, but the readout matters as ophthalmology continues to be a Phase 3 register hub for peptide programs (Palatin's PL9643 melanocortin-4 receptor agonist for dry eye) that would follow the same combination-with-standard-of-care commercial pattern if approved.